Drug Formulary Committee (DFC)
DFC plays a key role in the management of the HA Drug Formulary and in the revision of the existing drug list.
Terms of Reference
The Terms of Reference of DFC are:
a)
To manage and review the HA Drug Formulary which serves as a standard and reference for all HA institutions;
b)
To conduct biennial comprehensive review of the HA Drug Formulary or upon request of DMC;
c)
To make recommendations for management and operation of the HA Drug Formulary to DMC;
d)
To advise DMC on the number of expert panels required for operation of the HA Drug Formulary; and
e)
To evaluate new drug applications which fall outside the scope of Drug Advisory Committee (DAC).
Composition
The DFC Chairperson would be elected among the DTC Chairpersons of all seven clusters for a term of 2 years, usually prior to the biennial comprehensive review of the HA Drug Formulary. Their tenure can be renewed upon consensus among the Cluster DTC Chairpersons. The DFC composition is designed to enable rational and balanced decisions-making to cater for the service needs of various clusters. DFC may co-opt additional members from the Expert Panels when necessary. The DFC composition is as follows:
a)
Corporate Director overseeing pharmaceutical service management;
b)
The remaining six chairpersons of Cluster DTC; and
c)
Chief Pharmacist.
All DFC members are positional appointments.